康艾注射液联合培美曲塞二线治疗非鳞状非小细胞肺癌54例疗效观察

目的 观察康艾注射液联合培美曲塞二线治疗中晚期非鳞状非小细胞肺癌的疗效及毒副反应.方法 选取本院胸部肿瘤科54例经病理学确诊,且经一线治疗失败的中晚期肺癌患者,随机分为2组.实验组用康艾注射液联合培美曲塞进行治疗,对照组单纯用培美曲塞进行治疗,以WHO疗效评价指标及毒副反应分度标准为依据,对比评价2组患者的近期疗效和毒副反应.结果 实验组与对照组比较,在近期疗效方面实验组好于对照组（P＜0.05）,在毒副反应方面,实验组白细胞计数、血红蛋白计数减少、（KPS）评分改善率优于对照组（P＜0.05）.结论 中晚期非鳞状非小细胞肺癌患者二线运用康艾注射液联合培美曲塞方案治疗,其临床近期疗效显著,减毒效果明显.

Kang Ai injection combined with pemetrexed as second line treatment of squamous non-small cell lung cancer： 54 cases of clinical curative effects

Objective Kang Ai injection combined with pemetrexed was used as the second - line treat- ment of non - small cell lung cancer. The local advanced squamous curative effect and adverse reaction-were examined. Methods The middle - late stage lung cancer 54 patientsin our hospitalwith confirmed pathology, and the first - line treatment failure were randomly divided into 2 groups. Experimental group used Kang Ai injection combined with pemetrexed effect （according to the WHO criteria of evaluation , control group usedpemetrexed alone. The curative index and index of adverse reaction）was evaluated. Results The near future curative effect of experimental group was better than that in control group （ P 〈 0.05 ）, in terms of adverse reaction, white blood cell count, hemoglobin count reduction, kamof - sky score period was better than that of control group （ P 〈 0.05 ）. Conclusion In middle -late non squa-mous peripheral non - small cell lung cancer patients, the use of Kang Ai injection combined with peme-trexed solution treatment is better inclinical curative effect, with less adverse reactions.